Will Janssen S New Class Of Type 2 Diabetes Drug Fare Better Than AZN

Janssen, a division of Johnson & Johnson (NYSE:JNJ) has submitted a new drug application for canagliflozin that belongs to a new class of drugs called SGLT2 inhibitors to treat type 2 diabetes. The drugmaker is surely hoping it fares better than its rivals AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb (NYSE:BMY) since the U.S. Food and Drug Administration

See more here

Related posts:

1. Bristol Myers AstraZeneca Achieve Main Goal Of Type 2 Diabetes Drug Study Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN) found their combination drug...
2. Bristol Myers Squibb And AstraZeneca Achieve Main Goal In Type 2 Diabetes Drug Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca (NYSE:AZN) announced today their phase...
3. FDA Extends Action Date For Type 2 Diabetes Drug The U.S. Food and Drug Administration has delayed making a...
4. Bristol Myers AstraZeneca Diabetes Drug Gets New Hope A glowing review by the prestigious Cleveland Clinic could give...
5. FDA Wants More Data On Diabetes Drug From Bristol Myers AstraZeneca Influencing Brain Aging: New research published in Nature suggests that...